#China #Shanghai #CAR T-cell Therapy #Satri-cel #CARsgen Therapeutics

CARsgen Therapeutics Reports 2025 Annual Results

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a leading biopharmaceutical company specializing in innovative CAR T-cell therapies, has recently disclosed its annual results for 2025, showcasing remarkable advancements in its product pipeline and financial standing.

Financial Highlights

As of December 31, 2025, the company reported cash and cash equivalents totaling approximately RMB 1.123 billion, with expectations to maintain over RMB 1 billion through 2026. The financial outlook remains positive, as CARsgen anticipates sustaining sufficient cash flow well into 2030. Notably, the net loss for the year decreased by around 87%, amounting to RMB 103 million compared to a substantial loss of RMB 798 million in 2024. This considerable reduction underscores the company’s operational efficiencies and focus on strategic cost management.

Revenue generated during 2025 was approximately RMB 125.7 million, primarily driven by zevor-cel, an autologous CAR T-cell therapy. This figure reflects the product's performance in the market, which is calculated based on manufacturing milestones rather than end-user pricing. The gross profit for the same period was reported to be around RMB 80 million, indicating solid commercial viability and cost-effectiveness in production.

Key Product Developments

CARsgen's zevor-cel, an autologous CAR T-cell therapy designed for treating adult patients with relapsed or refractory multiple myeloma (R/R MM), has made waves since its approval by the National Medical Products Administration (NMPA) of China. In 2025, the company accelerated its commercialization efforts, culminating in 218 confirmed orders placed through its partner Huadong Medicine, which has actively promoted the therapy across various provinces in China.

A significant achievement for 2025 was zevor-cel's inclusion in the China Commercial Health Insurance Innovative Drug Catalogue, enhancing its accessibility for patients. The updated clinical data from ongoing trials continues to demonstrate its efficacy and safety, promising robust market growth moving forward.

Furthermore, the satri-cel product, which is aimed at treating Claudin18.2-positive advanced gastric cancers, received Breakthrough Therapy Designation and Priority Review by the NMPA. Expected for approval in the first half of 2026, satri-cel is positioned to be a trailblazer for CAR T-cell therapies aimed at solid tumors worldwide, with recent trial results showcasing encouraging survival statistics compared to conventional treatments.

CARsgen is also advancing its research into allogeneic CAR T-cell therapies, underlining its commitment to developing products capable of serving broad patient populations. Utilizing its proprietary THANK-uCAR® and THANK-u Plus™ platforms, the company is developing multiple candidates targeting hematologic malignancies and autoimmune diseases, further expanding its therapeutic reach.

Expansion and Future Directions

In a strategic move, CARsgen announced plans to enhance its commercial manufacturing capabilities by partnering with a key enterprise in Shanghai. With an investment of RMB 370 million, this facility will significantly bolster CARsgen's production and operational capabilities in alignment with international standards. This initiative aims to streamline the production of CAR T-cell therapies and strengthen the company’s position in the global market.

Dr. Zonghai Li, the Founder and CEO of CARsgen, emphasized the pivotal nature of 2025 for the company, expressing optimism about the forthcoming commercialization phases and the anticipated market impact of therapies like satri-cel. The transformative potential of allogeneic CAR T-cell therapies is set to reshape treatment paradigms for patients suffering from diverse malignancies.

Conclusion

As CARsgen Therapeutics pursues its vision to innovate and deliver cutting-edge cell therapies, the future appears promising, not only for the company but also for the patients who stand to benefit from improved therapeutic options. With a strong pipeline and strategic operational focus, CARsgen is on track to expand its influence in the biopharmaceutical landscape, aiming ultimately to make significant strides in the fight against cancer and other critical health challenges.

For further updates on CARsgen's developments and innovations, visit their official website.